Revance Therapeutics to Release First Quarter 2017 Financial Results Tuesday, May 9, 2017
April 25 2017 - 4:05PM
Business Wire
- Conference Call Scheduled for Tuesday, May 9,
2017 at 4:30pm ET -
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology
company developing botulinum toxin products for use in aesthetic
and therapeutic indications, today announced that the company will
release first quarter 2017 financial results on Tuesday, May 9,
2017 after the close of market. Revance will host a corresponding
conference call and a live webcast at 1:30pm PT/4:30pm
ET on the same day to discuss the results and provide a
business and pipeline update.
Individuals interested in listening to the conference call may
do so by dialing (855) 453-3827 for domestic callers, or (484)
756-4301 for international callers and reference conference ID:
3251601; or from the webcast link in the investor relations section
of the company's website at: www.revance.com.
A replay of the call will be available beginning May 9,
2017 at 4:30pm PT/7:30pm ET to May 10, 2017 at
4:30pm PT/7:30pm ET. To access the replay, dial (855) 859-2056 or
(404) 537-3406 and reference Conference ID: 3251601. The webcast
will be available in the investor relations section on the
company's website for 30 days following the completion of the
call.
About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is
committed to the advancement of remarkable science. The company is
developing a portfolio of products for aesthetic medicine and
underserved therapeutic specialties, including dermatology,
orthopedics and neurology. Revance's science is based upon a
proprietary peptide technology, which when combined with active
drug molecules, may help address current unmet needs. Revance's
initial focus is on developing daxibotulinumtoxinA, the company's
highly purified botulinum toxin, for a broad spectrum of aesthetic
and therapeutic indications, including facial wrinkles and muscle
movement disorders.
The company's lead drug candidate, DaxibotulinumtoxinA for
Injection (RT002), is currently in development for the treatment of
glabellar lines, cervical dystonia and plantar fasciitis with the
potential to be the first long-acting neuromodulator. The company
holds worldwide rights for all indications of RT002 injectable and
RT001 topical and the pharmaceutical uses of its proprietary
peptide technology platform. More information on Revance may be
found at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170425006046/en/
Investors:Revance TherapeuticsJeanie Herbert,
714-325-3584jherbert@revance.comorBurns McClellanAmi Bavishi,
212-213-0006abavishi@burnsmc.comorTrade Media:Nadine Tosk,
504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024